Markets:

Overview

News

Currencies

International

Treasuries

Abbott Laboratories (NY:ABT)

112.21 +0.02 (+0.02%)

Official Closing Price Updated: 7:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Abbott Laboratories

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

47 48 Next >

New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market ↗

May 24, 2023

Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies’ (NASDAQ: BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in Ne

Via Benzinga

Abbott's Baby Formula Brouhaha: Judge Says No Harm, No Foul in Contamination Controversy ↗

May 23, 2023

U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Abbott Laboratories (NYSE: ABT) Similac and other formulas that they said had...

Via Benzinga

Looking At Abbott Laboratories's Recent Unusual Options Activity ↗

May 23, 2023

Via Benzinga

Stereotaxis, Abbott Ink Pact To Combine Mapping & Robotic Tech: FDA Approves Abbott's Next-Gen Abalation Catheter ↗

May 19, 2023

Stereotaxis Inc (NYSE: STXS) shares are gaining after the company announced a global collaboration with Abbott Laboratories (NYSE: ABT) to integrate Abbott's EnSite X EP System with Stereotaxis' <

Via Benzinga

Back Off, Chronic Pain! FDA Nods for Abbott's Spinal Cord Stimulation Devices ↗

May 16, 2023

The FDA approved Abbott Laboratories (NYSE: ABT) spinal cord stimulation (SCS) devices for chronic back pain in people who have not had or are not eligible to receive back surgery, known as

Via Benzinga

(ABT) - Analyzing Abbott Laboratories's Short Interest ↗

May 16, 2023

Via Benzinga

A Look Into Abbott Laboratories Inc's Price Over Earnings ↗

May 15, 2023

Via Benzinga

Abbott Laboratories Unusual Options Activity For May 10 ↗

May 10, 2023

Via Benzinga

Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years ↗

May 05, 2023

Via Benzinga

Claims of PediaSure Boosting Children's Height Challenged in Lawsuit Against Abbott Laboratories ↗

May 16, 2023

A New York City woman has reportedly sued Abbott Laboratories (NYSE: ABT), accusing them of misleading consumers into believing its PediaSure nutrition drinks were "clinically proven" to increase...

Via Benzinga

Investing for the Long-Term? Here are 7 Must-Have Dividend Stocks ↗

May 14, 2023

Here are seven must-have dividend stocks for long-term investing that you can consider for your dividend stock portfolio.

Via InvestorPlace

Cramer Asks Investors To Focus On Individual Stocks Over Macro Strategies: Says Don't 'Miss The Trees For The Forest' ↗

May 09, 2023

Via Benzinga

3 Dividend Stock Warning Signs That Could Portend Trouble ↗

May 06, 2023

Recognizing these red flags will help you avoid investing in weaker businesses.

Via The Motley Fool

Is Dexcom a Good Stock to Buy Now? ↗

May 02, 2023

A poorly received first-quarter earnings report has investors wondering if this stock's best days are behind it.

Via The Motley Fool

Looking At Abbott Laboratories's Recent Unusual Options Activity ↗

April 28, 2023

Via Benzinga

Got $1,000? 2 Top Dividend Stocks to Buy Now ↗

April 28, 2023

Passive income can add to your stock market winnings.

Via The Motley Fool

If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today ↗

April 27, 2023

Via Benzinga

3 Stocks to Buy Before They Soar to New Heights in 2023 ↗

May 01, 2023

Here are three stocks to buy, for investors looking for companies on the cusp of a potential breakout driven by secular growth catalysts.

Via InvestorPlace

Why Abbott Laboratories Stock Looks Ridiculously Overpriced ↗

April 27, 2023

Abbott's stock is trading at a huge premium, and it isn't a justifiable one for investors.

Via The Motley Fool

7 Healthcare Stocks With Huge Return Potential for Long-Term Investors ↗

April 27, 2023

These leading healthcare companies have proven that they can deliver reliable gains to their shareholders over many years and decades.

Via InvestorPlace

The Fed Predicts a Recession: Should You Still Buy Stocks Now? ↗

April 25, 2023

The Fed expects a "mild" downturn.

Via The Motley Fool

Sleep Easy With These 2 Rock-Solid Dividend Stocks ↗

April 25, 2023

They aren't in any danger of crimping their dividends.

Via The Motley Fool

This Supercharged Dividend King Stock Might Soon Run Out of Steam ↗

April 25, 2023

Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.

Via The Motley Fool

Is Abbott Laboratories Stock a Buy for Dividend Investors? ↗

April 25, 2023

This healthcare company stands out among its peers as a Dividend King.

Via The Motley Fool

Abbott Laboratories Unusual Options Activity ↗

April 21, 2023

Via Benzinga

This Company's Non-Invasive Tech Looks To Be Unique In the Market And Can Help People Take Ownership Over Monitoring Their Health ↗

April 25, 2023

The need for noninvasive healthcare technology that allows people to take ownership and gather more insight into their health became acute when COVID revealed the fragility of the hospital system.

Via Benzinga

Is Abbott Laboratories Still a Good Dividend Stock to Buy? ↗

April 23, 2023

A better-than-expected first-quarter report already pushed it much higher.

Via The Motley Fool

Stock Market Rally Drifts Lower; Tesla Dives On Margins; ISRG, DHI, LVS Are Winners: Weekly Review ↗

April 21, 2023

The major indexes saw modest declines, holding in a range.

Via Investor's Business Daily

P/E Ratio Insights for Abbott Laboratories ↗

April 21, 2023

Via Benzinga

Healthcare Sector Update: MedTech Trending Up ↗

April 20, 2023

Earnings from major device companies and large-cap biopharma over the next two weeks will help us ascertain risks for the market.

Via Talk Markets

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

47 48 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Abbott Laboratories (NY:ABT)

Headline News about Abbott Laboratories

Starting at $3.75/week.

Subscribe Today